Related Experiment Video
Updated: May 22, 2026

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae
Published on: September 17, 2020
Rapamycin slows aging in mice
John E Wilkinson1, Lisa Burmeister, Susan V Brooks
1Unit for Laboratory Animal Medicine and Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Abstract:
Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action.
Insights
Rapamycin extends lifespan in mice by slowing multiple aging aspects, not just preventing cancer. However, it also causes harmful side effects like testicular degeneration and cataracts.
Area of Science:
- Gerontology and pharmacology
- Molecular biology and aging research
Background:
- Rapamycin is known to increase lifespan in mice.
- Its precise mechanism, whether solely through anti-cancer effects or broader anti-aging properties, remains under investigation.
Purpose of the Study:
- To investigate if rapamycin slows multiple aging processes in mice beyond its effects on neoplastic diseases.
- To identify potential adverse effects of rapamycin treatment on aging-related changes.
Main Methods:
- Treatment of mice with rapamycin starting at 9 months of age.
- Assessment of age-dependent changes in various tissues (heart, liver, adrenal glands, endometrium, tendon) and spontaneous activity.
- Evaluation of the incidence of neoplastic diseases, testicular degeneration, and cataracts.
Main Results:
- Rapamycin treatment significantly slowed age-dependent changes in multiple organs and spontaneous activity.
- These effects suggest rapamycin retards multiple aspects of aging in mice.
- However, rapamycin treatment also led to a higher incidence of testicular degeneration and cataracts.
Conclusions:
- Rapamycin demonstrates broad anti-aging effects in mice, impacting various physiological systems.
- The drug's potential therapeutic benefits must be weighed against adverse effects.
- Further research is needed to optimize rapamycin's timing, dosage, and tissue-specific actions for clinical application, particularly concerning inhibitors of TOR (target of rapamycin) action.
Related Concept Videos
Replicative Cell Senescence
Replicative Cell Senescence
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

